Radiopharmaceutical therapy (RPT) is emerging as a safe and effective targeted approach
to treating many types of cancer. In RPT, radiation is systemically or locally delivered using …

Breast cancer is the most frequent type of malignancy in women worldwide, and drug
resistance to the available systemic therapies remains a major challenge. At the molecular …

The International Commission on Radiation Units and Measurements (ICRU), since its
inception in 1925, has had as its principal objective the development of internationally …

Targeted alpha therapy (TAT) using alpha particle-emitting radionuclides is in the spotlight
after the approval of 223RaCl2 for patients with metastatic castration-resistant prostate …

Highlights•Nanocarriers with the ability to target tumors are being increasingly explored.•
Nanomedicine aid in maintaining a balance between efficacy and toxicity.•Recent advances …

α-Emitting radionuclides have been approved for cancer treatment since 2013, with
increasing degrees of success. Despite this clinical utility, little is known regarding the …

Radiopharmaceuticals are rapidly developing as a field, with the successful use of targeted
beta emitters in neuroendocrine tumors and prostate cancer serving as catalysts. Targeted …

Targeted alpha therapy is an oncological treatment, where cytotoxic doses of alpha radiation
are locally delivered to tumor cells, while the surrounding healthy tissue is minimally …

Nuclear medicine is defined as the use of radionuclides for diagnostic and therapeutic
applications. The imaging modalities positron emission tomography (PET) and single …

Cells exposed to ionizing radiation undergo a series of complex responses, including DNA
damage, reproductive cell death, and altered proliferation states, which are all linked to cell …